Plain-English translation of NCT07059845 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new drug called for ovarian cancer patients whose tumors have a specific protein marker called folate receptor alpha. The medication will be given intravenously (through an IV) either alone or combined with standard cancer treatments like or . The trial will test different dose levels to find which combination works best and has the fewest side effects.
Ovarian cancer remains a serious disease with many deaths each year, and patients need better treatment options. This medication is designed to target a specific feature found on ovarian cancer cells, offering a potentially new way to treat this disease either as a first-line therapy or for patients whose cancer has come back.
You likely qualify if…
You likely don't qualify if…
You will be assigned to one of three substudies and receive intravenous infusions of the new medication, sometimes combined with and/or , at a hospital or clinic. Over approximately 2.5 to 3 years, you will have frequent visits for medical check-ups, blood tests, and imaging scans to see how the treatment is working and monitor for side effects. The study involves more visits and tests than standard treatment, so be prepared for a higher treatment burden than you may normally experience.
AI-generated summary from trial data · Sep 5, 2026 · Not medical advice
United States